Manganese (Mn) is an essential nutrient with the capacity for toxicity from excessive exposure. Accumulation of Mn in the striatum, globus pallidus, and other midbrain regions is associated with neurotoxicity following high-dose Mn inhalation. Physiologically based pharmacokinetic (PBPK) models for ingested and inhaled Mn in rats and nonhuman primates were previously developed. The models contained saturable Mn tissue-binding capacities, preferential fluxes of Mn in specific tissues, and homeostatic control processes such as inducible biliary excretion of Mn. In this study, a nonhuman primate model was scaled to humans and was further extended to include iv, ip, and sc exposure routes so that past studies regarding radiolabeled carrierfree 54 MnCl 2 tracer kinetics could be evaluated. Simulation results accurately recapitulated the biphasic elimination behavior for all exposure routes. The PBPK models also provided consistent crossspecies descriptions of Mn tracer kinetics across multiple exposure routes. These results indicate that PBPK models can accurately simulate the overall kinetic behavior of Mn and predict conditions where exposures will increase free Mn in various tissues throughout the body. Simulations with the human model indicate that globus pallidus Mn concentrations are unaffected by air concentrations < 10 mg/m 3 Mn. The use of this human Mn PBPK model can become a key component of future human health risk assessment of Mn, allowing the consideration of various exposure routes, natural tissue background levels, and homeostatic controls to explore exposure conditions that lead to increased target tissue levels resulting from Mn overexposure.
Manganese (Mn) is an essential nutrient with the capacity for toxicity from excessive exposure. Accumulation of Mn in the striatum, globus pallidus, and other midbrain regions is associated with neurotoxicity following high-dose Mn inhalation. Physiologically based pharmacokinetic (PBPK) models for ingested and inhaled Mn in rats and nonhuman primates were previously developed. The models contained saturable Mn tissue-binding capacities, preferential fluxes of Mn in specific tissues, and homeostatic control processes such as inducible biliary excretion of Mn. In this study, a nonhuman primate model was scaled to humans and was further extended to include iv, ip, and sc exposure routes so that past studies regarding radiolabeled carrierfree 54 MnCl 2 tracer kinetics could be evaluated. Simulation results accurately recapitulated the biphasic elimination behavior for all exposure routes. The PBPK models also provided consistent crossspecies descriptions of Mn tracer kinetics across multiple exposure routes. These results indicate that PBPK models can accurately simulate the overall kinetic behavior of Mn and predict conditions where exposures will increase free Mn in various tissues throughout the body. Simulations with the human model indicate that globus pallidus Mn concentrations are unaffected by air concentrations < 10 mg/m 3 Mn. The use of this human Mn PBPK model can become a key component of future human health risk assessment of Mn, allowing the consideration of various exposure routes, natural tissue background levels, and homeostatic controls to explore exposure conditions that lead to increased target tissue levels resulting from Mn overexposure.
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The essential trace element manganese (Mn) is found in all human tissues and is required for numerous physiological processes, including protein and carbohydrate metabolism, immune system function, and bone growth. The primary source of Mn exposure is through the diet, with adult human consumption ranging from 1 to 10 mg Mn/day, of which approximately 1-5% is absorbed by the gastrointestinal (GI) tract ATSDR, 2000; Freeland-Graves, 1994) . Homeostatic controls tightly restrict Mn absorption and regulate Mn excretion to maintain stable tissue levels despite fluctuations in daily Mn dietary exposure.
Neurotoxicity can occur when Mn intake exceeds elimination resulting in Mn accumulation in midbrain regions that influence motor control such as the globus pallidus, striatum, and substantia nigra (Dorman et al., 2006b; Yamada et al., 1986) . Similar neurological responses have been linked to prolonged high-dose Mn inhalation (Pal et al., 1999) or drinking water ingestion (Kawamura et al., 1941) , impaired Mn clearance because of liver dysfunction (Spahr et al., 1996) , and long-term parenteral nutrition (Fell et al., 1996) . To understand the risk to humans from excessive Mn exposure, it is important to determine the exposure conditions that result in Mn concentrations in the brain that are increased significantly compared with brain Mn concentrations arising from normal dietary intake (Andersen et al., 1999) .
Inhalation has historically been the exposure route of most concern for Mn because inhaled Mn particles that deposit on lung epithelium bypass uptake control in the GI tract and liver and directly enter the systemic circulation. Prolonged exposure to high levels (> 1 mg/m 3 ) of Mn-laden dusts in occupational settings such as mining can result in severe Mn-induced neurotoxicity, including the onset of manganism, an extrapyramidal movement disorder that is similar but clinically distinguishable from Parkinson's disease Pal et al., 1999) . Neurological effects of a subclinical nature have been reported in workers with chronic inhalation to lower concentrations (0.5-1.0 mg/m 3 ) of Mn in the workplace (Iregren, 1990; Lucchini et al., 1995 Lucchini et al., , 1999 Mergler et al., 1994; Myers et al., 2003; Roels, et al., 1987 Roels, et al., , 1992 Roels, et al., , 1999 Young et al., 2005) . Other studies have indicated that environmental exposures may also be associated with subtle, subclinical neurological changes in the general population (Finkelstein and Jerrett, 2007; Lucchini et al., 2007; Mergler et al., 1999; Rodriguez-Agudelo et al., 2006) . Concerns regarding chronic low-level Mn inhalation exposure have led to the development of an extensive Mn pharmacokinetic data set and physiologically based pharmacokinetic (PBPK) models. This series of pharmacokinetic modeling studies described Mn kinetics using compartmental models (Teeguarden et al., 2007a,b,c) , PBPK models of adult rats and monkeys (Nong et al., 2008 (Nong et al., , 2009 , and PBPK models of gestation and lactation in rats (Yoon et al., 2009a,b) . The first Mn compartmental pharmacokinetic models used linear exchange rates to simulate Mn tissue kinetics under normal and deficient dietary conditions but were unable to capture the rapid rise in tissue Mn concentrations seen during inhalation exposure to high Mn concentrations. An enhanced model structure allowed tissue compartments to retain fairly constant Mn levels during normal dietary intake and included saturable Mn tissue stores that increased rapidly under inhalation exposure conditions (Nong et al., 2009) . These PBPK modeling efforts produced a consistent description of Mn tissue kinetics in rats and monkeys following dietary and inhalation exposures (Andersen et al., 2010) .
In the current study, the previous PBPK model for rats and monkeys (Nong et al., 2009) MnCl 2 ) implicitly reflects the overall kinetics of Mn in the body.
MATERIALS AND METHODS
PBPK model structure. The PBPK model structure contained compartments for the liver, lung, nasal cavity, bone, blood, cerebellum, olfactory bulb, globus pallidus, and pituitary gland (Fig. 1) . Remaining body tissues were combined into a single compartment. The same model structure was used for monkeys and humans. A thorough description of the model parameters and underlying equations are given in Nong et al. (2008 Nong et al. ( , 2009 Mn tracer kinetics from oral and inhalation exposure and by ip, iv, and sc administration.
Inhalation exposure was to MnSO 4 particles, which are highly soluble in mucus and tissue (Vitarella et al., 2000) . Aerosol parameters for MnSO 4 consisted of a mass median aerodynamic diameter of 2.0 lm, a geometric SD of 1.5 and a particle density of 2.95 g/cm 3 (Dorman et al., 2006a) . Fractional deposition of inhaled MnSO 4 particles in the respiratory tract was calculated using the Multiple-Path Particle Dosimetry model (MPPD version 2.0; Anjilvel and Asgharian, 1995; Asgharian et al., 2001 ; available at http://www. thehamner.org). Nasal deposition estimates from the MPPD model were partitioned onto the respiratory and olfactory epithelium based on speciesdependent airflow allocation (Kepler et al., 1998; Schroeter et al., 2010) . Deposited Mn was assumed to be rapidly absorbed from lung tissues and nasal respiratory epithelium into the systemic circulation or transported from the nasal olfactory epithelium to the olfactory bulb.
Absorption of Mn by the GI tract is dose dependent. As dietary Mn levels increase, GI absorption decreases and biliary excretion increases (Dorman et al., 2001b; Teeguarden et al., 2007b) . These homeostatic controls are overwhelmed when Mn exposure is high, leading to increases in free Mn tissue levels. The fraction of Mn absorbed by the GI tract (Fdietup) and the biliary excretion rate constant (kbilec) were calibrated based on steady-state tissue concentrations and 54 Mn whole-body elimination curves. Induction of biliary elimination of Mn was included to describe increased bile elimination that was directly observed in higher exposure concentrations in monkeys (Nong et al., 2009) . The biliary elimination rate constant was dependent on blood Mn concentration:
where k bile0 is the basal biliary excretion rate constant, k bmax is the maximal increase in the excretion rate constant, k b50 is the arterial concentration at half the induced level of Mn in the arterial blood (C art ), and n is the slope factor. C art was used as a surrogate for free Mn liver concentrations, the presumed driver for Mn excretion, because Mn blood levels were directly measured in monkeys (Dorman et al., 2006a; Nong et al., 2009) . A simplified GI tract was used in the Mn PBPK model by Nong et al. (2009) because there was no need to track unabsorbed or absorbed Mn after it was excreted in the bile. Modifications were made to this GI structure to include fecal excretion (to be consistent with the data from Newland et al., 1987) and simulate tracer kinetics of 54 Mn administered orally in monkeys and humans. A series of gut compartments were added that were consistent with the physiology of Mn absorption by the GI tract (Fig. 1) . Fdietup represents the fraction of dietary Mn that was absorbed in the GI tract and was available to the systemic circulation. This process was described as a direct transfer from the gut lumen to the liver. The remaining fraction of Mn (1 À Fdietup) in the gut lumen was absorbed by the gut epithelium and stored in enterocytes or transferred to the lower GI tract lumen and excreted through the feces. F ent 3 k GI represents the storage rate constant of the enterocytes in the gut epithelium, where F ent is the fraction stored by the enterocytes and k GI is the rate constant for movement from the gut lumen. Mn transfer from the gut epithelium to the lower GI tract was by sloughing of enterocytes (k ent ) from the epithelial layer. The stored Mn in enterocytes was eventually excreted into feces without entering the systemic circulation because of enterocyte turnover. Mn elimination from the body through the feces was governed by the rate constant k feces .
The following biologically informed assumptions were made concerning distribution of absorbed Mn. All tissues contain both free and bound Mn. Free Mn circulates in the blood throughout the body. Bound Mn is stored in tissue constituents where it participates in various physiological functions. Mn binding is a reversible, saturable process described by tissue-specific association (k a ) and dissociation (k d ) rate constants. The distribution between bound and free Mn is determined by the dissociation binding ratio (k d /k a ). The maximal binding capacity (B max ) constrains the levels of bound Mn in each tissue; saturation of the binding capacity with increasing exposure concentration leads to increases in concentrations of free Mn in each tissue. The rate of change of free Mn in each tissue depends on their respective binding rate constants and maximal binding capacity. Certain brain regions in monkeys exposed to higher doses of Mn by inhalation have preferential increases in tissue Mn (Dorman et al., 2006a) . Selective increases in brain Mn in some tissues following inhalation exposure could not be accurately simulated using only dissociation processes. Differential increases in free Mn in the four brain regions (globus pallidus, pituitary, cerebellum, and olfactory bulb) were described by asymmetric diffusion rate constants from tissue blood into tissue and back (k in and k out ). In addition, the globus pallidus and pituitary influx rates were modified by introducing a concentration-dependent influx rate constant (Nong et al., 2009) :
where k in0 is the basal influx rate constant, k inmax is the maximal influx rate, k in50 is the affinity rate constant, and A free is the amount of free Mn in the respective brain region. Defining an increase in tissue influx rate constant as free Mn increases was needed to describe changes in Mn concentrations in these brain regions that could not be sufficiently described by association and dissociation rate constants. The rate of change of free Mn in brain regions depends on diffusional clearance into and out of the tissues and on the binding rate constants and binding capacity in each tissue. In addition to dietary and inhalation exposure routes, model components were included to account for administration of 54 Mn by ip, iv, and sc injection (Fig. 1) . Iv and sc injections were input directly into the venous blood; ip injections were simulated by placing the majority of the injected dose directly into the liver, consistent with uptake by the highly vascularized GI tissue. A small fraction of the ip dose (F IP ) was absorbed into the peritoneal cavity where it was slowly released (k IP ) into the liver.
Monkey model parameterization. Physiological and anatomical parameters for the monkey PBPK model were obtained from Davies and Morris (1993) , Dorman et al. (2006a) , and Nong et al. (2009) (Table 1) . A body weight of 2.5 kg was used in the monkey inhalation exposure simulations to be consistent with body weights reported by Dorman et al. (2006a) . Basal Mn tissue levels (Table 2) were set to tissue measurements in control monkeys fed a commercial diet containing 133 ppm Mn (Dorman et al., 2006a) by adjusting the parameters governing dietary absorption (Fdietup) and biliary elimination (kbilec) ( Table 3 ). Nasal and lung deposition fractions for the monkey were scaled from the rat by nasal epithelial surface area and pulmonary ventilation, respectively. As reported by Nong et al. (2009) , Mn nasal and lung deposition values were 40 and 27%, respectively. Nasal deposition was further divided FIG. 1. The PBPK model structure describing Mn tissue kinetics in adult monkeys and humans. In each tissue compartment, the amount of bound Mn is in equilibrium with the assumed binding capacity (B tissue ) and free Mn. Tissue-binding processes were controlled by association and dissociation rate constants (k a and k d ). Free Mn moves in the blood throughout the body and is stored in each tissue as bound Mn. Influx and efflux diffusion rate constants (k in and k out ) control preferential increases in free Mn in brain regions. Q P , Q C , and Q tissue refer to pulmonary ventilation, cardiac output, and tissue blood flows.
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at CIIT on August 13, 2015 http://toxsci.oxfordjournals.org/ into respiratory and olfactory deposition according to an airflow allocation of 9% olfactory and 91% respiratory (Kepler et al., 1998) .
Dissociation rate constants (k a and k d ), tissue binding capacities (B max ), and diffusion parameters (k in and k out ) in each tissue compartment were calibrated to the pharmacokinetic data from Dorman et al. (2006a) . In that study, monkeys were exposed by inhalation to MnSO 4 exposure atmospheres for 90 days (6 h/day, 5 days/week) at concentrations of 0, 0.06, 0.3, or 1.5 mg Mn/m 3 . Tissues were collected on the day following the last Mn exposure to determine tissue Mn concentrations. Dissociation rate constants and maximal binding capacities were adjusted so that each brain region contained approximately 60% bound Mn under dietary exposure only (i.e., with no inhalation). These parameters reflect a change in bound Mn fraction from that reported by Nong et al. (2009) (approximately 20% bound Mn) to provide a more consistent description of Mn binding in brain regions across animal species. Diffusion parameters were then adjusted to simulate the rise in brain Mn tissue levels following the onset of inhalation exposure and the subsequent decrease in Mn brain tissue concentrations following the end-of-the exposure period. Further refinements to brain kinetics in the globus pallidus and pituitary regions were included by adding the dose-dependent influx term so that simulations accurately predicted the rise in Mn tissue levels in these regions. Tissue binding and diffusion parameters are listed in Table 4 .
Human model parameterization. Physiological parameters in the human PBPK model were either scaled from the monkey or were obtained from the literature (Brown et al., 1997) (Table 1 ). An average body weight of 70 kg was used in all simulations. Human basal Mn tissue levels were obtained from autopsy reports (Table 2) . Dietary intake was set at 3 mg/day Mn, a value slightly higher than the adequate intake level . Dietary absorption (Fdietup) and biliary excretion (kbilec) were calibrated to whole-body elimination kinetics from iv tracer doses of 54 Mn (Table 3 ) (Mahoney and Small, 1968; Mena et al., 1967) .
Human respiratory tract deposition of MnSO 4 particles was estimated with MPPD using standard ventilatory parameters for resting nasal breathing in adults: 12 breaths per minute and a tidal volume of 625 ml. Nasal and lung deposition were estimated to be 37.6 and 25%, respectively. Deposition on human olfactory epithelium was assumed to be 5% of total nasal deposition based on olfactory airflow allocation (Schroeter et al., 2010) .
Interspecies scaling from monkeys to humans was based on allometric scaling for flows (BW 0.75 ) and volumes body weight (BW). For the initial human model parameterization, diffusion rate constants for brain compartments a Calibrated with a 133-ppm Mn diet to the data from Dorman et al. (2006a) . b Calibrated using a 3 mg/day Mn diet to the data from Mahoney and Small (1968) and Mena et al. (1967) . Calibrated to the data from Furchner et al. (1966) . f Calibrated to the data from Davidsson et al. (1988) . (Molokhia, 1967 Table 4 .
Inhalation exposure simulations. Mn inhalation exposure was simulated in monkeys for 90 days (6 h/day, 5 days/week) to be consistent with the study by Dorman et al. (2006a) . Mn inhalation exposures in humans were simulated for 90 days (8 h/day, 5 days/week), unless otherwise noted.
RESULTS
Mn Tracer Kinetics in Monkeys
The Mn PBPK model simulated 54 Mn tracer kinetics in monkeys exposed by ip, iv, and sc injection and by oral and inhalation routes. Exposure routes were selected based on whole-body elimination or fecal excretion data available from 54 Mn tracer kinetic studies in monkeys. Fractional dietary absorption (Fdietup) and biliary excretion (kbilec) were adjusted for each exposure scenario to account for the different Mn diets and body weights used in each study (Table 5) . These parameters were calibrated to maintain the basal tissue Mn levels reported by Dorman et al. (2006a) prior to exposure and to fit whole-body retention or fecal excretion data of 54 Mn. All the other parameters in the PBPK model were unchanged to maintain a consistent description of Mn tissue kinetics regardless of exposure route.
In the study by Dastur et al. (1971) , 12 rhesus monkeys with an average body weight of 2.5 kg were administered an ip dose of 200 lCi of carrier-free 54 MnCl 2 solution. Whole-body activity of 54 Mn was reported up to 278 days postexposure. The amount of Mn in the diet was not stated, so an 80-ppm Mn diet was used to be consistent with other published studies (Furchner et al., 1966) . Because this was lower than the 133-ppm Mn diet used by Dorman et al. (2006a) for model calibration, Fdietup was increased to 0.00345 to calibrate steady-state tissue Mn levels. Rapid elimination of 54 Mn from the body was observed in the first 50 days following ip injection. This phase was followed by a slow phase of Kinetic parameters for the human model were adjusted from the monkey parameters to maintain the basal tissue levels in Table 2 with no Mn inhalation.
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elimination for the remaining time. The parameters F IP ¼ 0.03 and k IP ¼ 1.0 3 10 À7 /h were calibrated to the whole-body elimination data to simulate the slow release of 54 Mn from the peritoneal cavity to the liver. With these adjustments to specific parameters, model simulations were consistent with the nonlinear kinetics of 54 Mn observed by ip administration (Fig. 2A) .
In the study by Furchner et al. (1966) , 0.6 lCi of carrier-free 54 MnCl 2 was administered iv to three rhesus monkeys with an average body weight of 8.5 kg. The monkeys were maintained on a commercial diet containing 80 ppm Mn. Whole-body 54 Mn activity was measured for 290 days. Fdietup was reduced to 0.0017 to account for the higher levels of Mn ingested by the larger monkeys and to maintain stable background Mn tissue levels. After 300 days, whole-body retention after ip and iv administration were very similar, but initial clearance was much faster after ip dosing ( Figs. 2A and 2B) . Furchner et al. (1966) also orally dosed three rhesus monkeys with 0.6 lCi of carrier-free 54 MnCl 2 . These monkeys had an average body weight of 7 kg and were also maintained on an 80-ppm Mn commercial diet. Whole-body activity of 54 Mn was measured for 23 days postexposure. Parameters governing GI absorption (k GI , F ENT , and k ENT ) were calibrated based on the oral 54 Mn tracer data. Fdietup was set to 0.002 to maintain consistent background Mn tissue levels. Rapid elimination of 54 Mn was observed in the first 5 days following oral administration of Mn that was not taken up systemically followed by a slow elimination phase for the remaining time period (Fig. 2C) .
In the study by Newland et al. (1987) , one monkey (Macaca nemistrina, 5 kg) received a 6-week continuous infusion of 54 Mn through two sc osmotic pumps implanted between the shoulder blades. Each solution contained 200 lCi 54 Mn and 400 mg Mn in an MnCl 2 solution. As noted by the authors, there was leakage at the osmotic pump implant sites, so the reported doses represent an estimate of the maximum dose as calculated from the pumping rate, and the actual dose received by the monkey could have been lower. For PBPK model simulations, the maximal dose as reported by Newland et al. (1987) Mn concentration was observed immediately following removal of the sc pumps (Fig. 3A) . This rapid elimination phase was followed by a slow elimination phase for the remaining observation period. Rapid clearance of 54 Mn following sc exposure appears to be because of dose rate differences and not to the route of administration. Because the osmotic pump solution contained a high concentration of carrier (400 mg of Mn), the kinetics are not equivalent to carrier-free radiotracer kinetics. Newland et al. (1987) exposed two anesthetized monkeys (Macaca fascicularis, 2.5 and 3.1 kg) to a nebulized aerosol of 54 MnCl 2 for 30 min through a tracheal tube. Each monkey was exposed to a different aerosol with different specific activities. Fecal gamma activity was reported for approximately 250 days. The lung dose for each aerosol was estimated to be 16% by Newland et al. (1987) . Calibrated dietary parameters in the PBPK model were Fdietup ¼ 0.001 and kbilec ¼ 0.015 to fit background Mn tissue levels and obtain fecal elimination rates consistent with the data. Fecal Mn declined rapidly in the first few days following exposure, followed by a slow decline for the remaining time period (Fig. 3B) .
Mn Tracer Kinetics in Humans
54 Mn tracer kinetics were also available for humans given an iv dose of 54 MnCl 2 . In the study by Mahoney and Small (1968) , three normal subjects (identified in Fig. 4 by their initials: HM, MM, and CH) were given an iv dose of 2.5 lCi of 54 Mn. Whole-body retention of 54 Mn was measured for 60 days. No information was given in the study regarding the subjects' gender, body weight, or diet. In another study by Mena et al. (1967) , eight healthy medical personnel were injected with an iv dose of 20 lCi 54 Mn, and whole-body retention was measured for 30 days. Observations of wholebody clearance of 54 Mn from both studies were consistent (Fig. 4) , with all subjects showing a gradual decrease in 54 Mn retention from near 100% at day 1 to about 40% on day 30. Additionally, whole-body retention in the three subjects in the study of Mahoney and Small (1968) decreased to 20-30% by day 60. Clearance curves revealed a fast elimination component in the first few days followed by a slow elimination component for the remaining time period, consistent with 54 Mn clearance observations in nonhuman primates and other species. Dietary absorption and biliary excretion rate constants in the human model were calibrated to the whole-body retention data from these two studies. The biliary excretion rate constant (kbilec ¼ 0.051) and biliary induction parameters were identical to those used for the monkey. Fractional dietary absorption was higher in humans (Fdietup ¼ 0.06) than in monkeys because of the lower amount of Mn in the human diet. Model simulations recapitulated the decrease in human whole-body retention of 54 Mn observed over the 60-day time frame (Fig. 4) .
To study dose-dependent effects of Mn intake on 54 Mn clearance rates, Mahoney and Small (1968) also analyzed whole-body retention of 54 Mn in subjects receiving supplemental Mn. One subject (subject JM) was on a voluntary reduced calorie diet (800 calories per day) for 6 months prior to the start of the study. This subject was given an iv dose of 2.5 lCi of 54 Mn at the start of the study, and whole-body retention was measured periodically. The reduced calorie diet was continued throughout the observation period. Sixty days after the 54 Mn injection, the subject began to ingest 800 mg/day of Mn with the whole-body retention data of Mahoney and Small (1968) and Mena et al. (1967) . The curve represents the model simulation; the symbols for the study of Mahoney and Small (1968) are retention data for individual subjects; and the symbols for the study of Mena et al. (1967) represent average retention from eight subjects. Fdietup ¼ 0.06, kbilec ¼ 0.051.
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Mn as an MnCl 2 solution. Whole-body retention measurements of 54 Mn continued for another 25 days to examine the effect of the ''flushing dose'' of ingested Mn on 54 Mn clearance (Fig. 5A) . Before the high Mn dose was ingested, whole-body retention was higher in the reduced calorie subject than in the normal subjects because of decreased biliary elimination from the presumably lower Mn in the calorie-restricted diet. At day 30, retention in the subject on the reduced calorie diet was about 65% compared with about 40% in normal subjects. After the high Mn ingestion period began, a rapid increase in 54 Mn clearance was observed. For the PBPK model simulations, the reduced calorie diet was simulated by assuming 1 mg Mn/day in the diet. As a result of the reduced calorie diet, Mn dietary absorption increased. Fdietup was increased slightly to 0.062 to fit the whole-body retention data until day 60. Once the flushing Mn dose was ingested, Fdietup was reduced to 0.00046 to account for decreased GI absorption of these high Mn oral doses. With these changes in dietary absorption corresponding to the different amounts of Mn ingested, the PBPK model simulations were consistent with 54 Mn wholebody retention data for this subject (Fig. 5A) .
To examine another high-dose Mn scenario, another subject (subject WS) in the study of Mahoney and Small (1968) that was on a normal diet was preloaded for 10 days prior to iv injection of 54 Mn by ingesting 300 mg Mn/day as an MnCl 2 solution. This dosing schedule continued throughout the experiment for an additional 40 days. The disappearance of 54 Mn from the body was much more rapid in the subject preloaded with Mn than in normal subjects (Fig. 5B) . Ten days after the 54 Mn iv injection, approximately 40% remained in the body compared with about 70% in normal subjects. For the model simulations, Mn dietary absorption was reduced by 28% per day for 15 days beginning at the start of the high-dose Mn ingestion. After 15 days, Fdietup was then kept constant at its reduced value of 0.00043 for the remainder of the exposure period. This adjustment accounts for the slow decrease in dietary absorption of Mn from moderately high doses over extended time periods (Fig. 5B) . Mahoney and Small (1968) also investigated 54 Mn retention in a mildly iron-deficient subject and found that 54 Mn clearance was faster in the iron-deficient subject than in normal subjects (Fig. 5C ). Fifty days after 54 Mn administration, iron therapy was initiated with 400 mg/day Fe. This immediately decreased the elimination rate of 54 Mn from the body. Model simulations recapitulated whole-body retention in this subject by increasing Mn absorption (Fdietup ¼ 0.075) during the iron-deficient phase and decreasing Mn absorption (Fdietup ¼ 0.035) after the initiation of iron therapy (Fig. 5C ). This behavior was consistent with previous findings where decreased Mn absorption was observed with high iron intake (Davis et al., 1992; Finley, 1999) . The interaction of Mn and Fe absorption is likely because of the fact that both metals share common uptake and storage transporters such as divalent metal transporter-1 and transferrin, so increases in the dietary Mn in human volunteers given supplemental Mn or Fe compared with the experimental data from Mahoney and Small (1968) : (A) subject JM was on a reduced calorie diet and began to ingest 800 mg/day Mn on day 60 of the study; (B) subject WS was preloaded with 300 mg/day Mn 10 days prior to the start of the study; (C) subject SM had an iron deficiency and began to ingest 400 mg/day Fe on day 50. The condition of each subject was accommodated in the PBPK model by adjusting Mn dietary absorption (Fdietup). The curves represent model simulations and the symbols are retention data from individual subjects.
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Oral Mn exposures were used to calibrate GI parameters in the PBPK model (Table 4 ). In the study by Davidsson et al. (1988) , whole-body retention of 54 Mn was measured in six women who ingested a meal labeled with 0.1 MBq 54 Mn (Fig. 6) . A wide range of elimination rates was observed in the subjects, but all showed rapid elimination in the first 10 days followed by a slow phase of elimination for the remaining period (Fig. 6) . The shape of the retention curve was similar to that observed in monkeys receiving an oral dose of 54 MnCl 2 (Fig. 2) . Fdietup and kbilec were increased twofold for this simulation to account for increased Mn dietary absorption and biliary excretion in women . Simulated plasma Mn concentrations were also compared with plasma Mn measurements from men consuming different levels of dietary Mn (Freeland-Graves, 1994 ). Although the model predicted larger differences in plasma Mn concentration at the lowest and highest dietary levels, model simulations accurately captured the trend of plasma Mn levels caused by changes in dietary Mn exposure (Fig. 7) .
Mn Inhalation Exposures in Monkeys and Humans
Basal tissue Mn levels were set to the measurements reported by Dorman et al. (2006a) for control monkeys on a 133-ppm Mn diet by adjusting dietary absorption and biliary excretion (Table 4) . The monkey PBPK model parameters were first scaled from the rat values and were further calibrated to the pharmacokinetic data in Dorman et al. (2006a) . Predicted brain tissue concentrations in monkeys were then compared with Mn concentrations observed in monkeys exposed for a 90-day period (Dorman et al., 2006a) . At an exposure concentration of 1.5 mg/m 3 Mn, predicted Mn tissue concentrations in the four brain regions (globus pallidus, pituitary, cerebellum, and olfactory bulb) were consistent with the rapid rise in tissue concentrations after the onset of high inhalation exposure followed by the decline to near basal levels in the 90 days following cessation of exposure (Fig. 8) . Predicted timedependent Mn tissue concentrations were also consistent with the rise in end-of-exposure brain tissue levels at different inhaled concentrations (Fig. 9) . Predicted Mn tissue concentrations were similar to those reported by Nong et al. (2009) except that wider fluctuations in brain Mn concentrations during inhalation were observed because of the increase in magnitude of the diffusional rate constants. In the human model, dietary absorption and biliary elimination were calibrated to 54 Mn whole-body retention data, as described previously (Table 3) . Dissociation rate constants, maximal tissue binding, and diffusion rate constants were first scaled from the monkey and were then adjusted to fit the basal Mn tissue levels under dietary exposure only, assuming a 3 mg/day Mn diet (Table 4) . Differences in parameter values between monkeys and humans are because of different basal Mn tissue levels between species (Table 2) . Predicted brain Mn concentrations in humans were obtained for an inhalation exposure period of 90 days (8 h/day, 5 days/ week) to simulate an occupational exposure and to be consistent with the inhalation exposure period used in the monkey simulations for direct comparison between species. Like monkeys, human brain Mn concentrations during this simulated exposure period exhibited a rapid rise in Mn tissue levels following the onset of exposure (Fig. 10) . This was followed by a slower decline in human Mn tissue levels following the end of the exposure period. Simulated Mn 
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concentrations in the human globus pallidus were also examined during a 90-day exposure to Mn concentrations of 0.01-5.0 mg/m 3 (Fig. 11) . At the lowest exposure concentration (0.01 mg/m 3 Mn), the model predicted no appreciable increase (< 1%) in brain Mn concentrations above background levels that result from normal dietary exposure. At an exposure concentration of 0.1 mg/m 3 , slight increases (~5%) in brain Mn concentration above background levels were observed during the inhalation exposure period. More significant (> 30%) increases in brain Mn concentrations were predicted at the higher exposure concentrations (> 1.0 mg/m 3 ).
Sensitivity Analysis
Sensitivity coefficients for predicted globus pallidus concentration from a 1% change in model parameter values were determined at inhalation exposure concentrations of 0.01, 0.1, and 1.0 mg/m 3 Mn in monkeys and humans (Table 6 ). Model predictions were most sensitive to the influx and efflux diffusion rate constants (k in and k out ). Model predictions were also sensitive to dietary absorption (Fdietup) and biliary elimination (kbilec), although predictions became less sensitive with increasing exposure concentration as brain Mn levels were driven more by inhalation than diet. Sensitivity toward tissuebinding constants (B max , k a , and k d ) decreased as inhalation exposure concentration increased because of saturation of the tissue-binding capacity. Sensitivity of model predictions displayed similar trends in monkeys and humans and were consistent with sensitivity results in rats (Nong et al., 2009) clearance studies that have been conducted in monkeys and humans. A common feature from all these studies was that 54 Mn clearance from the body follows biphasic elimination, with a short ''fast'' elimination phase (with halftimes of around a few days) followed by a longer ''slow'' elimination phase. This elimination behavior was consistently observed with all exposure routes. The availability of tracer studies for multiple exposure routes permitted a comparison of dose route differences in elimination. The fastest clearance in monkeys and humans occurred from oral exposure, whereas the slowest clearance occurred following iv administration. Oral clearance has a component related to limited GI uptake and passage of 95-99% of the oral dose through the GI tract into feces. The ability of the models to accurately replicate the elimination phases observed in these tracer studies provides confidence that the PBPK model structure accurately depicts the key aspects of Mn pharmacokinetics in monkeys and humans, irrespective of exposure route. Cotzias and Greenough (1958) and Dorman et al. (2001b) showed that 54 Mn clearance rates were affected by dietary Mn levels in mice and rats, respectively. Rats and mice given high Mn diets had significantly higher clearance rates when compared with animals kept on lower Mn diets. Similar findings were observed in humans by Mahoney and Small (1968) , where a subject on a reduced calorie diet (which presumably resulted in lower Mn intake) had a much reduced elimination rate than subjects on a normal Mn diet. These effects arise from adaptive responses in Mn kinetics as oral doses vary. Model simulations reproduced the clearance rates of the individual on the reduced calorie diet by slightly increasing dietary absorption. The biliary excretion rate constant was reduced in the model simulations for this Mn-deficient individual because they also had decreased biliary elimination as evidenced by their reduced whole-body carrier-free 54 Mn exhibited similar behavior across dose routes and species, dose dependencies became more apparent when high levels of supplemental (carrier) Mn were added. In the study by Mahoney and Small (1968) , subjects receiving 300-800 mg Mn/day had higher clearance rates than subjects on normal Mn diets alone. Similar observations were also made by Cotzias and Greenough (1958) who observed rapid 54 Mn clearance in mice receiving high doses of carrier Mn. These results were also consistent with those of Newland et al. (1987) , where a monkey exposed to an sc tracer dose of 54 Mn with 400 mg of carrier Mn exhibited rapid clearance of the radiotracer. Clearance rates observed in this sc exposure were much faster than those seen following inhalation exposure (Newland et al., 1987) . Although Newland originally attributed these retention differences to a presumed slow-release Mn depot in the lung, it is more likely because of dose-dependent differences in Mn elimination caused by the large dose of carrier-free Mn. PBPK model simulations were able to accurately recapitulate all these dose-dependent scenarios by adjusting dietary absorption and controlling Mn tissue concentrations by dose-dependent inducible elimination rates.
Similar dose dependencies were observed in the case of inhalation exposure. Mena et al. (1967) Mn miners just removed from the mines, and in miners diagnosed with chronic Mn poisoning who had been removed from the mines several years prior to the study. Whole-body clearance of 54 Mn was faster in the active miners than in the other groups presumably because of their elevated Mn body burden. Although the miners diagnosed with Mn poisoning had also worked in the mines, they were removed from the Mn exposures long enough that tissue Mn levels had likely returned to near normal, and thus, they exhibited clearance rates similar to those reported in healthy individuals. This behavior was also demonstrated with the human PBPK model by comparing simulated clearance of 54 Mn in people exposed to different Mn exposure concentrations by inhalation (Fig. 12 ). In the model simulations, inhalation exposures started the day of the 54 Mn iv injection and lasted for 60 days (8 h/day, 5 days/week). Simulated exposure concentrations were 0, 0.01, 0.1, and 1.0 mg/m 3 , spanning a range of concentrations that have been observed in human Mn exposure studies. At an exposure concentration of 0.01 mg/m 3 , there was virtually no change in 54 Mn turnover from air-exposed controls. However, at the highest exposure concentration (1 mg/m 3 ), simulated 54 Mn elimination was rapidly increased because of the higher body burden and increased biliary excretion of Mn from the inhalation exposures. These predictions in humans were also consistent with the findings of Dorman et al. (2001a) who found that rats exposed by inhalation to high Mn concentrations (0.3 mg Mn/m 3 ) had faster 54 Mn clearance rates. Tracer studies in rats, monkeys, and humans reveal similar findings: clearance behavior displays biphasic kinetics, there are dose route differences in elimination, and clearance rates depend on total Mn body burden either from Mn in diet or supplemental Mn exposures. Because tracer studies implicitly reflect the kinetics of Mn disposition, these studies reflect the dose dependencies of inducible biliary elimination on Mn levels in the body. The ability of the PBPK models to provide consistent multispecies descriptions of Mn tracer kinetics across multiple exposure routes indicates that the models have captured the dose-dependent characteristics of Mn disposition and can accurately predict conditions where exposures will increase free Mn in various tissues throughout the body above background levels from normal dietary exposure.
The ability of the human PBPK model to predict Mn tissue dosimetry based on pharmacokinetic data in laboratory animals depends on a consistent description of Mn kinetics across species. There are significant physiological and biochemical differences between rats, monkeys, and humans that had to be accounted for in the interspecies PBPK models, including tissue volumes, blood flows, pulmonary ventilation, and less well-understood processes regulating Mn uptake and storage. Direct allometric scaling of model parameters from the rat was often not adequate to describe Mn tissue kinetics in other species. However, the availability of Mn pharmacokinetic time courses in multiple species and 54 Mn clearance data in rats, monkeys, and humans allowed us to make further adjustments to model parameters beyond simple use of generic allometric scaling approaches to accurately describe Mn tissue dosimetry across multiple species. Although model parameters were changed beyond scaling, the underlying mechanisms governing Mn uptake and elimination (inducible biliary excretion, tissuebinding processes, and asymmetric diffusion fluxes) were preserved among species, providing confidence that a PBPK model with a consistent structure across species can accurately predict exposure conditions in humans that result in Mn tissue accumulation.
One of the primary species differences that affect Mn kinetics is diet. This difference is important to account for in the PBPK models because Mn is an essential nutrient. PBPK models for essential metals must account for dose-dependent biological processes that regulate absorption, tissue storage, and elimination. Concerns arise when exposure exceeds elimination capability. Laboratory animals are often maintained on diets that contain relatively high Mn concentrations, whereas the human diet is typically much lower in Mn (ranging from 1 to 10 mg/day). When Mn dietary intake is increased, homeostatic controls regulate Mn body burden by decreasing intestinal absorption and increasing biliary elimination. These processes were included in the PBPK model through use of the parameter Fdietup, which controls the amount absorbed by the GI tract, and kbilec, which is the biliary excretion rate constant induced by Mn blood concentration. With higher Mn exposure, blood Mn concentrations increase, resulting in increased biliary elimination. The maximum induction factor implemented in the model was 2.5-fold, which was reached at higher exposure concentrations (1.5 mg/m 3 ). Lung dose is an important determinant for subsequent Mn tissue dosimetry calculations resulting from inhalation exposure. Pulmonary ventilation and lung airway structure differ significantly between species. Deposition estimates for Mn 
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particles incorporated species-specific lung geometries, ventilatory rates, and particle properties by use of particle deposition software (MPPD) to estimate regional respiratory tract deposition. Because the monkey lung morphology was not available in MPPD, surface area scaling from the rat was used to obtain monkey respiratory tract deposition estimates. Deposition estimates using this scaling procedure were consistent with those reported by Cheng et al. (2008) , where deposition of aerosol droplets was measured in the upper respiratory tract and lungs of monkeys. MnSO 4 particles were used in this study because they were used in the monkey inhalation studies by Dorman et al. (2006a) and are more bioavailable than other less soluble forms (e.g., MnO 2 and MnPO 4 ). Adjustments can be made to lung absorption parameters based on solubility to predict pharmacokinetics and dosimetry of other forms of Mn.
Another important difference between species is in the olfactory region. Whereas the rat olfactory epithelium comprises almost 50% of the total nasal surface area, in monkeys and humans, it is about 9 and 5%, respectively. This difference will influence the amount of Mn delivered to the olfactory bulb via the olfactory pathway. Olfactory delivery did not make a significant contribution to striatal Mn levels in the rat (Leavens et al., 2007) , and magnetic resonance imaging in nonhuman primates showed no significant signal intensities in the tissues connecting the olfactory bulb and midbrain regions (Dorman et al., 2006b ). These studies indicate that similar kinetic mechanisms may be at work in humans for delivery of Mn to the olfactory bulb. Nonetheless, the current model structure included olfactory transport in monkeys and humans even though the contribution of this route to midbrain tissues is minimal.
As inhalation exposure concentration increases, homeostatic controls associated with biliary elimination are overwhelmed by increased input rates because of pulmonary Mn absorption. At higher inhaled concentrations (> 0.1 mg/m 3 ), binding capacities and biliary clearance processes become saturated, allowing free Mn to accumulate in the tissues (Fig. 13) . Tissuebinding rate constants (k a and k d ) and binding capacities (B max ) determine the ratios of bound versus free Mn in each tissue. The most toxicologically relevant metric for human Mn neurotoxicity is likely tissue concentration of free Mn in the globus pallidus and other midbrain regions. A comparison of rat, monkey, and human predictions of Mn concentrations in the globus pallidus (and rat striatum) reveals that all species exhibited similar behavior upon increasing levels of inhalation exposure (Fig. 14) , although the magnitude increases in brain Mn concentrations were slightly different among species. Predicted human globus pallidus Mn concentrations were less than those predicted in monkeys at exposure concentrations > 0.1 mg/m 3 but were very similar to those seen in the rat striatum. The larger magnitude changes predicted in monkeys compared with humans at higher inhalation exposure concentrations may be because of saturation of Mn binding sites in the monkey due to higher Mn concentrations in the diet. To test the sensitivity of Mn binding, further simulations were conducted assuming an equal bound Mn fraction (60% bound Mn fraction with no inhalation exposure) in humans and monkeys. Under these conditions, Mn globus pallidus concentrations in the human increased slightly faster than when an 80% bound fraction was used but still did not approach the levels observed in the monkey.
The human PBPK model can identify ranges of inhalation exposure concentrations where Mn levels in target tissues (specifically the globus pallidus) do not increase appreciably above background levels. Brain Mn concentrations begin to increase when subchronic (90 day) exposure concentrations rise to near 0.1 mg Mn/m 3 (Fig. 14) . This was also evident in the time course predictions (Fig. 11) increased slightly (by about 5%) over background levels at an exposure concentration of 0.1 mg/m 3 and increased dramatically for higher exposure concentrations. These data are consistent with derivations of benchmark concentrations for subclinical neurological effects from occupational studies at concentrations of 0.2 mg/m 3 (Clewell et al., 2003) .
CONCLUSION
Risk assessments for Mn, as an essential element, should consider its essentiality as well as its toxicity. Homeostatic controls maintain relatively stable Mn tissue concentrations by regulating dietary absorption, compartmental transfer, and biliary excretion under low levels of Mn exposure. Toxicity may occur under conditions of excessive exposure when these homeostatic controls are overwhelmed. The PBPK models presented in this study account for background tissue levels associated with dietary exposure and simulate simultaneous exposure to Mn by ingestion and inhalation. Simulation results accurately recapitulated the rapid increase in tissue Mn from high inhalation concentrations and subsequent return to basal levels following inhalation exposures in monkeys and described clearance of tracer doses in monkeys and humans under normal dietary conditions and with supplemental Mn doses. The human model was validated against available Mn tracer data and was able to accurately capture Mn elimination dynamics following iv exposure to tracer Mn. Consistent interspecies descriptions of Mn kinetics show that the models can accurately predict exposure conditions that will result in increased tissue concentrations in humans and can be used in a dosimetry-based risk assessment (Andersen et al., 1999) to identify exposure conditions that may lead to increased target tissue doses of this essential element.
SUPPLEMENTARY DATA
Supplementary data are available online at http://toxsci. oxfordjournals.org/.
FIG. 14. Simulated end-of-exposure tissue Mn levels (total Mn) in the rat striatum and monkey and human globus pallidus. The simulated rat striatal Mn levels are from Nong et al. (2009) and are compared with data (mean ± SE) from Dorman et al. (2004) and Tapin et al. (2006) . The simulated monkey globus pallidus Mn levels are compared with data from Dorman et al. (2006a) . Rats and monkeys were exposed to 6 h/day, 5 days/week for 90 days. Humans were exposed to 8 h/day, 5 days/week for 90 days. 
